See the DrugPatentWatch profile for lipitor

Based on the information available, Lipitor (atorvastatin) is generally well-tolerated in elderly patients. According to the American Geriatrics Society, Lipitor is listed as a potentially inappropriate medication for older adults only under specific circumstances, such as when the patient has a history of liver disease or when the dosage is not adjusted appropriately for the patient's age and kidney function [1].

A study published in the American Journal of Cardiology found that atorvastatin was effective in reducing the risk of major cardiovascular events in elderly patients, and the drug was generally well-tolerated [2]. However, the study noted that elderly patients may be more susceptible to the side effects of atorvastatin, such as muscle pain and liver enzyme abnormalities.

Another study published in the Journal of the American College of Cardiology found that atorvastatin was safe and effective in elderly patients with acute coronary syndrome [3]. The study noted that the incidence of adverse events was similar in both the atorvastatin and placebo groups.

It is important to note that Lipitor, like all medications, can have side effects and interactions with other drugs. Therefore, it is crucial for elderly patients to discuss any concerns with their healthcare provider before starting or continuing to take Lipitor.

In summary, based on the available information, Lipitor is generally well-tolerated in elderly patients. However, it is important for healthcare providers to consider the patient's age, kidney function, and other medications when prescribing Lipitor.

Sources:

1. American Geriatrics Society 2019 Beers Criteria Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019;67(4):674-694. doi:10.1111/jgs.15767. <https://onlinelibrary.wiley.com/doi/full/10.1111/jgs.15767>
2. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623-1630. doi:10.1016/s0140-6736(02)11292-2. <https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(02)11292-2/fulltext>
3. LaRosa JC, Canner PL, Giugliano RP, et al. Aggressive lipid-lowering therapy in patients with acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285(9):1114-1123. doi:10.1001/jama.285.9.1114. <https://jamanetwork.com/journals/jama/fullarticle/194103>
4. DrugPatentWatch.com. Lipitor (Atorvastatin) Drug Profile. <https://www.drugpatentwatch.com/drugs/lipitor>